The abstract is read at the publisher; the summary is JClub's.
In the phase 1/2 TRANSCEND CLL 004 study, liso-cel plus ibrutinib in R/R CLL/SLL achieved a 45% CR/CRi rate at DL2.
- Why it matters: The approach targets a key need for effective therapies in relapsed/refractory CLL/SLL, where durable responses and tolerable safety remain challenging.
- What they did: Patients received liso-cel at 50 × 106 (DL1) or 100 × 106 (DL2) CAR-positive T cells with concurrent ibrutinib, and investigators assessed CR/CRi as the primary endpoint.
- The result: At DL2, overall response rate was 86% and median progression-free survival was 31.4 months; safety was predictable, with cytokine release syndrome in 80% and no grade 4/5 CRS.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.